Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.

Sio Gene Therapies Inc (SIOX)

Sio Gene Therapies Inc (SIOX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Help
Go To:
Sio Gene Therapies Announces Fiscal Year 2021 Year-End Financial Results Globe Newswire - Tue Jun 14, 2022

NEW YORK and DURHAM, N.C., June 14, 2022 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (NASDAQ: SIOX) today provided financial results for its fiscal year...

SIOX : 0.4780 (+1.70%)
Sio Gene Therapies Provides Corporate Update Globe Newswire - Wed Apr 27, 2022

-Company Announces Termination of Licensing Agreement for GM1 and GM2 Gene Therapies with the University of Massachusetts-Company has engaged SVB...

SIOX : 0.4780 (+1.70%)
Sio Gene Therapies Announces Corporate Updates and Fiscal Third Quarter 2021 Financial Results Globe Newswire - Fri Feb 11, 2022

Company prioritizing industry-leading clinical-stage programs, AXO-AAV-GM1 and AXO-AAV-GM2, the first potential disease-modifying therapies for GM1...

SIOX : 0.4780 (+1.70%)
Sio Gene Therapies to Present at the 18th Annual WORLDSymposium™ 2022 Globe Newswire - Wed Feb 2, 2022

NEW YORK and DURHAM, N.C., Feb. 02, 2022 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (NASDAQ: SIOX), a clinical-stage company focused on developing...

SIOX : 0.4780 (+1.70%)
Sio Gene Therapies Announces Prioritization of Lead Gene Therapy Programs in GM1 and GM2 Gangliosidosis, Extension of Cash Runway, and CEO Transition Globe Newswire - Mon Jan 31, 2022

– Company to prioritize industry-leading clinical-stage programs, AXO-AAV-GM1 and AXO-AAV-GM2, the first potential disease-modifying therapies for GM1...

SIOX : 0.4780 (+1.70%)

Barchart Exclusives

Were There Many Surprises In Monday Morning's Markets? Barchart - Mon Dec 29, 6:10AM CST
Much of what we saw overnight was expected, even the collapse in silver to a certain degree. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot